Cover Image
QR Code

Infliximab: a review of its use in the treatment of Crohn's disease.

Infliximab is a chimeric monoclonal antibody to human tumor necrosis factor alpha. While its use was developed in the treatment of rheumatologic diseases its effects on Crohn's disease have revolutionized the management of this chronic illness. Infliximab has effects on both immune and epithelial ce...

Full description

Published in:Clinical Medicine: Therapeutics no. 1; pp. 1351 - 1366
Main Authors: Molloy JW, Stengel JZ, Arnold HL
Format: review Journal Article
Published: Sage Publications Inc. 2009
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105215156&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105215156
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11791713
        B02Y
      jtl: Clinical Medicine: Therapeutics
      issn: 11791713
      maglogo: Y
    pubinfo:
      dt: 2009
      iid: 1
      pid: 344
      pub: Sage Publications Inc.
      place: Thousand Oaks, California
    artinfo:
      ui:
        105215156
        105215156
        2010671914
        105215156
      ppf: 1351
      ppct: 15
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Infliximab: a review of its use in the treatment of Crohn's disease.
      aug:
        au:
          Molloy JW
          Stengel JZ
          Arnold HL
        affil: Gastroenterology Service, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, TX
      sug:
        subj:
          Crohn Disease Therapy
          Infliximab Therapeutic Use
          Antibodies Physiology
          Antibodies, Monoclonal Therapeutic Use
          Cell Physiology
          Clinical Trials
          Crohn Disease Classification
          Crohn Disease Complications
          Crohn Disease Physiopathology
          Crohn Disease Surgery
          Crohn Disease Symptoms
          Disease Remission
          Epithelium
          Immunity
          Inflammation Physiopathology
          Infliximab Administration and Dosage
          Infliximab Pharmacodynamics
          Infliximab Pharmacokinetics
          Outcomes (Health Care)
          Patient Care Methods
          Safety
          Surgery, Operative Methods
          Tumor Necrosis Factor Physiology
      ab: Infliximab is a chimeric monoclonal antibody to human tumor necrosis factor alpha. While its use was developed in the treatment of rheumatologic diseases its effects on Crohn's disease have revolutionized the management of this chronic illness. Infliximab has effects on both immune and epithelial cells leading to a reduction in gut inflammation and collagen deposition which promotes wound healing. Large randomized trials have proven efficacy of the drug in luminal and fistulizing Crohn's disease. Over time our understanding of antibody formation and long-term tolerability of the drug have refined our use of infliximab, eliminating episodic dosing and utilizing concomitant immunomodulator therapy to improve efficacy. Questions remain regarding top-down strategies, length of therapy, cost, reduction in surgical procedures, and the determination of which patients will respond best to any strategy chosen.
      pubtype: Academic Journal
      doctype:
        review
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N